S&P 500   4,297.50 (+0.41%)
DOW   33,924.81 (+0.49%)
QQQ   332.74 (+0.71%)
AAPL   173.03 (+0.54%)
MSFT   293.85 (+0.66%)
META   181.04 (+0.30%)
GOOGL   122.07 (+0.32%)
AMZN   143.05 (-0.35%)
TSLA   931.76 (+3.52%)
NVDA   188.06 (+0.52%)
NIO   21.31 (+0.95%)
BABA   93.95 (-0.87%)
AMD   100.65 (-0.18%)
MU   64.64 (-0.62%)
T   18.45 (+0.99%)
CGC   3.87 (+17.27%)
GE   79.75 (-0.23%)
F   16.37 (+1.17%)
DIS   124.56 (+2.46%)
AMC   23.43 (-4.13%)
PYPL   101.60 (+0.49%)
PFE   49.64 (-0.94%)
NFLX   248.62 (-0.27%)
S&P 500   4,297.50 (+0.41%)
DOW   33,924.81 (+0.49%)
QQQ   332.74 (+0.71%)
AAPL   173.03 (+0.54%)
MSFT   293.85 (+0.66%)
META   181.04 (+0.30%)
GOOGL   122.07 (+0.32%)
AMZN   143.05 (-0.35%)
TSLA   931.76 (+3.52%)
NVDA   188.06 (+0.52%)
NIO   21.31 (+0.95%)
BABA   93.95 (-0.87%)
AMD   100.65 (-0.18%)
MU   64.64 (-0.62%)
T   18.45 (+0.99%)
CGC   3.87 (+17.27%)
GE   79.75 (-0.23%)
F   16.37 (+1.17%)
DIS   124.56 (+2.46%)
AMC   23.43 (-4.13%)
PYPL   101.60 (+0.49%)
PFE   49.64 (-0.94%)
NFLX   248.62 (-0.27%)
S&P 500   4,297.50 (+0.41%)
DOW   33,924.81 (+0.49%)
QQQ   332.74 (+0.71%)
AAPL   173.03 (+0.54%)
MSFT   293.85 (+0.66%)
META   181.04 (+0.30%)
GOOGL   122.07 (+0.32%)
AMZN   143.05 (-0.35%)
TSLA   931.76 (+3.52%)
NVDA   188.06 (+0.52%)
NIO   21.31 (+0.95%)
BABA   93.95 (-0.87%)
AMD   100.65 (-0.18%)
MU   64.64 (-0.62%)
T   18.45 (+0.99%)
CGC   3.87 (+17.27%)
GE   79.75 (-0.23%)
F   16.37 (+1.17%)
DIS   124.56 (+2.46%)
AMC   23.43 (-4.13%)
PYPL   101.60 (+0.49%)
PFE   49.64 (-0.94%)
NFLX   248.62 (-0.27%)
S&P 500   4,297.50 (+0.41%)
DOW   33,924.81 (+0.49%)
QQQ   332.74 (+0.71%)
AAPL   173.03 (+0.54%)
MSFT   293.85 (+0.66%)
META   181.04 (+0.30%)
GOOGL   122.07 (+0.32%)
AMZN   143.05 (-0.35%)
TSLA   931.76 (+3.52%)
NVDA   188.06 (+0.52%)
NIO   21.31 (+0.95%)
BABA   93.95 (-0.87%)
AMD   100.65 (-0.18%)
MU   64.64 (-0.62%)
T   18.45 (+0.99%)
CGC   3.87 (+17.27%)
GE   79.75 (-0.23%)
F   16.37 (+1.17%)
DIS   124.56 (+2.46%)
AMC   23.43 (-4.13%)
PYPL   101.60 (+0.49%)
PFE   49.64 (-0.94%)
NFLX   248.62 (-0.27%)
NASDAQ:ATRC

AtriCure - ATRC Stock Forecast, Price & News

$52.87
+0.89 (+1.71%)
(As of 08/15/2022 02:43 PM ET)
Add
Compare
Today's Range
$51.86
$52.89
50-Day Range
$35.10
$51.98
52-Week Range
$32.83
$89.18
Volume
11,336 shs
Average Volume
265,621 shs
Market Capitalization
$2.45 billion
P/E Ratio
45.58
Dividend Yield
N/A
Price Target
$75.86

AtriCure MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
44.3% Upside
$75.86 Price Target
Short Interest
Healthy
3.74% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.57mentions of AtriCure in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.09) to ($0.89) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

257th out of 1,127 stocks

Surgical & Medical Instruments Industry

22nd out of 113 stocks

ATRC stock logo

About AtriCure (NASDAQ:ATRC) Stock

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

AtriCure Stock Up 2.5 %

NASDAQ:ATRC opened at $51.98 on Monday. The stock has a 50 day moving average price of $43.44 and a 200-day moving average price of $52.72. AtriCure has a one year low of $32.83 and a one year high of $89.18. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.93 and a current ratio of 3.66. The company has a market capitalization of $2.41 billion, a P/E ratio of 44.81 and a beta of 1.20.

AtriCure (NASDAQ:ATRC - Get Rating) last announced its earnings results on Tuesday, August 2nd. The medical device company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.02). AtriCure had a net margin of 17.62% and a negative return on equity of 11.47%. During the same quarter in the previous year, the firm earned ($0.30) EPS. As a group, equities analysts predict that AtriCure will post -1.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ATRC. Piper Sandler dropped their price target on shares of AtriCure from $90.00 to $55.00 and set an "overweight" rating for the company in a research report on Wednesday, August 3rd. Stifel Nicolaus decreased their price target on AtriCure from $70.00 to $50.00 in a report on Monday, July 18th. Needham & Company LLC upped their price objective on AtriCure from $55.00 to $65.00 and gave the stock a "buy" rating in a research note on Wednesday, August 3rd. StockNews.com raised AtriCure from a "sell" rating to a "hold" rating in a research note on Monday. Finally, BTIG Research lowered their price target on AtriCure from $94.00 to $75.00 and set a "buy" rating on the stock in a report on Friday, June 24th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, AtriCure currently has a consensus rating of "Moderate Buy" and an average target price of $75.86.

Receive ATRC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter.

ATRC Stock News Headlines

AtriCure (NASDAQ:ATRC) Cut to "Sell" at StockNews.com
AtriCure (NASDAQ:ATRC) Lowered to Sell at StockNews.com
Biden Executive Order 14017 Potentially Sending Lithium Stocks Skyrocketing
The White House is scared of our country's lithium supply running out. That's why Biden issued executive order 14017 to figure out how to expand our lithium production. And this is GREAT news for one company who's gobbling up land in the lithium-rich Nevada desert.
AtriCure (NASDAQ:ATRC) PT Lowered to $55.00 at Piper Sandler
AtriCure (NASDAQ:ATRC) PT Raised to $65.00
Elon Musk is Worried about China
China controls 80% of the lithium market and Tesla needs a lot of lithium for its cars. But a junior miner just discovered a once-in-a-lifetime deposit of this "white gold."
Is AtriCure (NASDAQ:ATRC) Using Too Much Debt?
AtriCure (ATRC) Set to Announce Quarterly Earnings on Tuesday
AtriCure (NASDAQ:ATRC) Cut to Sell at StockNews.com
See More Headlines
Receive ATRC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter.

ATRC Company Calendar

Last Earnings
8/02/2022
Today
8/15/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:ATRC
CUSIP
04963C20
Employees
875
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$75.86
High Stock Price Forecast
$110.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+43.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$50.20 million
Pretax Margin
17.68%

Debt

Sales & Book Value

Annual Sales
$274.33 million
Cash Flow
$0.97 per share
Book Value
$10.53 per share

Miscellaneous

Free Float
45,125,000
Market Cap
$2.45 billion
Optionable
Optionable
Beta
1.20

Social Links















ATRC Stock - Frequently Asked Questions

Should I buy or sell AtriCure stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATRC shares.
View ATRC analyst ratings
or view top-rated stocks.

What is AtriCure's stock price forecast for 2022?

5 Wall Street research analysts have issued 12 month price objectives for AtriCure's stock. Their ATRC share price forecasts range from $50.00 to $110.00. On average, they predict the company's share price to reach $75.86 in the next twelve months. This suggests a possible upside of 45.9% from the stock's current price.
View analysts price targets for ATRC
or view top-rated stocks among Wall Street analysts.

How have ATRC shares performed in 2022?

AtriCure's stock was trading at $69.53 at the beginning of the year. Since then, ATRC shares have decreased by 25.2% and is now trading at $51.98.
View the best growth stocks for 2022 here
.

When is AtriCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our ATRC earnings forecast
.

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) released its quarterly earnings data on Tuesday, August, 2nd. The medical device company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.30) by $0.02. AtriCure had a net margin of 17.62% and a negative trailing twelve-month return on equity of 11.47%. During the same period last year, the firm posted ($0.30) earnings per share.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure updated its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share (EPS) guidance of -$1.12--$1.07 for the period, compared to the consensus earnings per share estimate of -$1.10. The company issued revenue guidance of $323.00 million-$333.00 million, compared to the consensus revenue estimate of $324.43 million.

What is Michael Carrel's approval rating as AtriCure's CEO?

38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend.

What other stocks do shareholders of AtriCure own?

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

Who are AtriCure's major shareholders?

AtriCure's stock is owned by a variety of institutional and retail investors. Top institutional investors include First Light Asset Management LLC (3.19%), Credit Suisse AG (2.41%), Loomis Sayles & Co. L P (1.99%), TimesSquare Capital Management LLC (1.95%), Fiera Capital Corp (1.53%) and Eagle Asset Management Inc. (1.41%). Insiders that own company stock include Angela L Wirick, Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Justin J Noznesky, M Andrew Wade, Mark A Collar, Mark A Collar, Michael H Carrel, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin and Vinayak Doraiswamy.
View institutional ownership trends
.

How do I buy shares of AtriCure?

Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $51.98.

How much money does AtriCure make?

AtriCure (NASDAQ:ATRC) has a market capitalization of $2.41 billion and generates $274.33 million in revenue each year. The medical device company earns $50.20 million in net income (profit) each year or $1.16 on an earnings per share basis.

How many employees does AtriCure have?

The company employs 875 workers across the globe.

Does AtriCure have any subsidiaries?

The following companies are subsidiares of AtriCure: SentreHEART.
Read More

When was AtriCure founded?

AtriCure was founded in 2000.

How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The official website for the company is www.atricure.com. The medical device company can be reached via phone at (513) 755-4100, via email at lynn@gilmartinir.com, or via fax at 513-755-4567.

This page (NASDAQ:ATRC) was last updated on 8/15/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.